Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer.

ABSTRACT:

Background

Bevacizumab is extensively used in the treatment of advanced non-small-cell lung cancer (NSCLC). Numerous clinical trials have proven the clinical efficacies of bevacizumab biosimilars (BB).

Objective

Our study aimed to compare the clinical outcomes between bevacizumab reference product (RP) and BB among advanced NSCLC patients in a real-world setting.

Design

We retrospectively analyzed stage IV metastatic NSCLC patients who were treated with bevacizumab as part of a combination therapy. Patients were categorized into chemotherapy (CT) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) groups. We compared the patients' characteristics, treatment efficacy, and adverse events between RP and BB in the two treatment groups.

Methods

SUBMITTER: Ou WF 

PROVIDER: S-EPMC11526195 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature